While nasopharyngeal cancer is relatively rare in the United States, it is more widespread in other parts of the world, including Asia and North Africa. Memorial Sloan-Kettering researchers showed that people with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy. A team of international investigators from North America and Hong Kong, led by a Memorial Sloan-Kettering radiation oncologist, reported that adding the drug bevacizumab (Avastin®) to the current standard therapy might prevent the spread of nasopharyngeal tumors to other parts of the body, prolonging the lives of patients.
Related People
